Funding agencies: This work was supported by grants from European Community contract number 222918 (REPLACES) FP7—Thematic priority HEALTH (PC), and Progetto Giovani Ricercatori Ministero Sanità 2008 (BP).
New synaptic and molecular targets for neuroprotection in Parkinson's disease
Article first published online: 23 AUG 2012
Copyright © 2013 Movement Disorders Society
Special Issue: The Vatican Conference on Neuroprotection in Parkinson's Disease
Volume 28, Issue 1, pages 51–60, January 2013
How to Cite
Calabresi, P., Di Filippo, M., Gallina, A., Wang, Y., Stankowski, J. N., Picconi, B., Dawson, V. L. and Dawson, T. M. (2013), New synaptic and molecular targets for neuroprotection in Parkinson's disease. Mov. Disord., 28: 51–60. doi: 10.1002/mds.25096
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 6 FEB 2013
- Article first published online: 23 AUG 2012
- Manuscript Accepted: 3 JUN 2012
- Manuscript Revised: 21 MAR 2012
- Manuscript Received: 13 FEB 2012
- synaptic plasticity;
- dopamine receptors;
- NMDA receptors;
- LRRK2, Parthanatos
The defining anatomical feature of Parkinson's disease (PD) is the degeneration of substantia nigra pars compacta (SNc) neurons, resulting in striatal dopamine (DA) deficiency and in the subsequent alteration of basal ganglia physiology. Treatments targeting the dopaminergic system alleviate PD symptoms but are not able to slow the neurodegenerative process that underlies PD progression. The nucleus striatum comprises a complex network of projecting neurons and interneurons that integrates different neural signals to modulate the activity of the basal ganglia circuitry. In this review we describe new potential molecular and synaptic striatal targets for the development of both symptomatic and neuroprotective strategies for PD. In particular, we focus on the interaction between adenosine A2A receptors and dopamine D2 receptors, on the role of a correct assembly of NMDA receptors, and on the sGC/cGMP/PKG pathway. Moreover, we also discuss the possibility to target the cell death program parthanatos and the kinase LRRK2 in order to develop new putative neuroprotective agents for PD acting on dopaminergic nigral neurons as well as on other basal ganglia structures. © 2013 Movement Disorder Society